文献速递心脑血管急症重症综合管理与镇静镇痛

阿替普酶清除脑室内出血治疗重症卒中:随机、多中心、多区域、安慰剂对照CLEAR III试验结果

Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial.
PubMed 文献 · Lancet · 2017-01-10
一句话结论脑室内出血且已置入常规脑室外引流者,阿替普酶脑室冲洗较生理盐水冲洗未显著改善180天功能结局(mRS≤3:48% vs 45%),但降低病死率、增加mRS 5比例。

CLEAR III为随机、双盲、安慰剂对照、多区域试验,纳入ICU内已常规放置脑室外引流、稳定非创伤性幕上脑出血体积小于30 mL、脑室内出血阻塞第三或第四脑室且无 underlying pathology 的患者500例,1:1自适应随机接受最多12剂、每8小时1 mg阿替普酶或0.9%生理盐水经脑室外引流给药。主要疗效终点180天mRS≤3在阿替普酶组48% vs 生理盐水组45%(RR 1.06,95%CI 0.88-1.28,p=0.554),无显著差异;校正脑室内出血体积和丘脑出血后差异3.5%(RR 1.08,95%CI 0.90-1.29,p=0.420)。180天病死率阿替普酶组46例(18%)vs 生理盐水组73例(29%)(HR 0.60,95%CI 0.41-0.86,p=0.006),但mRS 5比例更高(42例[17%] vs 21例[9%],RR 1.99,95%CI 1.22-3.26,p=0.007)。脑室炎(17例[7%] vs 31例[12%],RR 0.55,95%CI 0.31-0.97,p=0.048)和严重不良事件(114例[46%] vs 151例[60%],RR 0.76,95%CI 0.64-0.90,p=0.002)阿替普酶组更少,症状性出血两组相似(6例[2%] vs 5例[2%],RR 1.21,95%CI 0.37-3.91

要点

  • 脑室内出血且已置入常规脑室外引流者,阿替普酶冲洗较生理盐水冲洗未显著改善180天功能结局(mRS≤3:48% vs 45%,RR 1.06,95%CI 0.88-1.28,p=0.554)。
  • 阿替普酶组180天病死率更低(18% vs 29%,HR 0.60,95%CI 0.41-0.86,p=0.006),但mRS 5比例更高(17% vs 9%,RR 1.99,95%CI 1.22-3.26,p=0.007)。
  • 阿替普酶组脑室炎(7% vs 12%,RR 0.55,95%CI 0.31-0.97,p=0.048)和严重不良事件(46% vs 60%,RR 0.76,95%CI 0.64-0.90,p=0.002)更少,症状性出血两组相似(2% vs 2%,RR 1.21,95%CI 0.37-3.91,p=0.771)。
  • 给药方案为经脑室外引流每8小时1 mg阿替普酶或0.9%生理盐水,最多12剂,每24小时复查CT。
  • 作者认为基于方案的阿替普酶联合脑室外引流似乎安全,但未来需研究更频繁的完全清除是否带来功能获益。

适用人群与场景

  • ICU内已常规放置脑室外引流、稳定非创伤性幕上脑出血体积小于30 mL、脑室内出血阻塞第三或第四脑室且无 underlying pathology 的患者。

诊断标准与关键阈值

  • 主要疗效终点:180天mRS≤3(由盲法评估者中心裁定)。
  • 每24小时复查CT以监测出血和脑室变化。

处置流程与药物剂量

  • 经脑室外引流给予阿替普酶1 mg或0.9%生理盐水,每8小时一次,最多12剂。
  • 给药期间每24小时复查CT。

红旗征与不能漏的情况

  • 症状性出血:阿替普酶组6例(2%)vs 生理盐水组5例(2%),RR 1.21(95%CI 0.37-3.91),p=0.771。
  • 脑室炎:阿替普酶组17例(7%)vs 生理盐水组31例(12%),RR 0.55(95%CI 0.31-0.97),p=0.048。

研究设计与关键结果

  • 随机、双盲、安慰剂对照、多区域试验,500例患者随机(阿替普酶组249例,生理盐水组251例),180天随访数据可分析者阿替普酶组246/249、生理盐水组245/251。
  • 主要疗效终点180天mRS≤3:阿替普酶组48% vs 生理盐水组45%,RR 1.06(95%CI 0.88-1.28),p=0.554;校正脑室内出血体积和丘脑出血后差异3.5%,RR 1.08(95%CI 0.90-1.29),p=0.420。
  • 180天病死率:阿替普酶组46例(18%)vs 生理盐水组73例(29%),HR 0.60(95%CI 0.41-0.86),p=0.006。
  • 180天mRS 5:阿替普酶组42例(17%)vs 生理盐水组21例(9%),RR 1.99(95%CI 1.22-3.26),p=0.007。
  • 严重不良事件:阿替普酶组114例(46%)vs 生理盐水组151例(60%),RR 0.76(95%CI 0.64-0.90),p=0.002。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照、多区域试验(CLEAR III)。
  • 作者结论:基于方案的阿替普酶联合脑室外引流似乎安全,但未显著改善mRS 3界值下的功能结局;未来需研究更频繁的完全清除是否带来功能获益。

对床旁实践的改变

  • 对于脑室内出血且已置入常规脑室外引流的患者,基于方案的阿替普酶脑室冲洗(每8小时1 mg,最多12剂)似乎安全,但未显著改善180天功能结局(mRS≤3:48% vs 45%)。
  • 作者认为未来需研究更频繁的完全清除是否带来功能获益。

指南或共识出处

  • CLEAR III试验,ClinicalTrials.gov注册号NCT00784134,资助方National Institute of Neurological Disorders and Stroke。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Intraventricular haemorrhage is a subtype of intracerebral haemorrhage, with 50% mortality and serious disability for survivors. We aimed to test whether attempting to remove intraventricular haemorrhage with alteplase versus saline irrigation improved functional outcome.

METHODS: In this randomised, double-blinded, placebo-controlled, multiregional trial (CLEAR III), participants with a routinely placed extraventricular drain, in the intensive care unit with stable, non-traumatic intracerebral haemorrhage volume less than 30 mL, intraventricular haemorrhage obstructing the 3rd or 4th ventricles, and no underlying pathology were adaptively randomly assigned (1:1), via a web-based system to receive up to 12 doses, 8 h apart of 1 mg of alteplase or 0·9% saline via the extraventricular drain. The treating physician, clinical research staff, and participants were masked to treatment assignment. CT scans were obtained every 24 h throughout dosing. The primary efficacy outcome was good functional outcome, defined as a modified Rankin Scale score (mRS) of 3 or less at 180 days per central adjudication by blinded evaluators. This study is registered with ClinicalTrials.gov, NCT00784134.

FINDINGS: Between Sept 18, 2009, and Jan 13, 2015, 500 patients were randomised: 249 to the alteplase group and 251 to the saline group. 180-day follow-up data were available for analysis from 246 of 249 participants in the alteplase group and 245 of 251 participants in the placebo group. The primary efficacy outcome was similar in each group (good outcome in alteplase group 48% vs saline 45%; risk ratio [RR] 1·06 [95% CI 0·88-1·28; p=0·554]). A difference of 3·5% (RR 1·08 [95% CI 0·90-1·29], p=0·420) was found after adjustment for intraventricular haemorrhage size and thalamic intracerebral haemorrhage. At 180 days, the treatment group had lower case fatality (46 [18%] vs saline 73 [29%], hazard ratio 0·60 [95% CI 0·41-0·86], p=0·006), but a greater proportion with mRS 5 (42 [17%] vs 21 [9%]; RR 1·99 [95% CI 1·22-3·26], p=0·007). Ventriculitis (17 [7%] alteplase vs 31 [12%] saline; RR 0·55 [95% CI 0·31-0·97], p=0·048) and serious adverse events (114 [46%] alteplase vs 151 [60%] saline; RR 0·76 [95% CI 0·64-0·90], p=0·002) were less frequent with alteplase treatment. Symptomatic bleeding (six [2%] in the alteplase group vs five [2%] in the saline group; RR 1·21 [95% CI 0·37-3·91], p=0·771) was similar.

INTERPRETATION: In patients with intraventricular haemorrhage and a routine extraventricular drain, irrigation with alteplase did not substantially improve functional outcomes at the mRS 3 cutoff compared with irrigation with saline. Protocol-based use of alteplase with extraventricular drain seems safe. Future investigation is needed to determine whether a greater frequency of complete intraventricular haemorrhage removal via alteplase produces gains in functional status.

FUNDING: National Institute of Neurological Disorders and Stroke.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Hanley DF, Lane K, McBee N, et al. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet. 2017. PMID: 28081952. doi:10.1016/S0140-6736(16)32410-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。